The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its future within the broader market now raises questions about future yields . Alternative versions are eroding market share, prompting concerns that investing in companies heavily reliant to Viagra's once-dominant influence could be a dangerous move , e